Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

ACCEL-SEVELAMER - Health Canada Drug Approval Details

Approvals/Health Canada/ACCEL-SEVELAMER

Authorized

STANDARD

ACCEL-SEVELAMER

accel pharma inc🇨🇦 Health Canada

Approval Date: Jul 4, 2025
Approval ID: d6d4412d9cb6beea
Company: accel pharma inc
Type: Standard

Approval Details

Approval Id: d6d4412d9cb6beea
Drug Approval Canada Name: ACCEL-SEVELAMER
Product Name: ACCEL-SEVELAMER
Status: Marketed
Status Date: 2017-11-08
Original Market Date: 2017-11-08
Din: 02461501
Drug Class: Human
Dosage Form: Tablet
Route Of Administration: Oral
Schedule: Prescription
Ahfs: 40:18.19
Atc Original: V03AE02 SEVELAMER
Atc Name: v 03 ae 02
Aig Number: 0152763001
Company Name: accel pharma inc
Company Address: 119 Labrosse Ave, Pointe Claire, Quebec, Canada, H9R 1A3

Active Ingredients

SEVELAMER CARBONATE

800 MG

Authorized

Quick Info

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

d6d4412d9cb6beea

Type

Standard

Back to Health Canada Approvals